Amorfix presents results from British blinded panel of spiked human blood samples



    TSX: AMF

    TORONTO, Feb. 11 /CNW/ - Amorfix Life Sciences Ltd. presented today the
decoded results of a blinded panel of spiked human blood samples, tested by
Amorfix's EP-vCJD(TM) assay, at the 12th Annual Transmissible Spongiform
Encephalopathies international conference. The samples had been provided by
the British National Institute for Biological Standards and Control (NIBSC).
    "The results show we have significantly improved our EP-vCJD(TM) assay
which was 10 times more sensitive in this more-extensive blinded panel
compared to the initial panel," said Dr. George Adams, Chief Executive
Officer, Amorfix. "In addition, we have now developed a potential confirmatory
assay which is 20 times more sensitive again and may be able to verify any
contaminated blood donation many years before the donor has symptoms of the
disease."
    The British Government has confirmed, the screening test, EP-vCJD(TM),
was able to detect with 100% accuracy spiked blood samples up to a 1:1,000,000
(1:100,000 of 10% homogenate) dilution of vCJD brain in blood. This
sensitivity was 10 times better than the previous blinded panel results
obtained with an earlier version of the assay and confirms Amorfix's internal
testing program. In addition, the assay was able detect with 100% accuracy
spiked blood samples up to a dilution of 1:10,000 (1:1000 dilution of 10%
homogenate) of vCJD spleen. Spleen has a lower amount of prions that are
believed to be similar to prions in the blood of people infected with vCJD.
    In addition, a test that uses larger volumes of blood has been developed
and can detect a 1:20,000,000 (1:2,000,000 of a 10% homogenate) dilution of
brain in blood. This test could be used to verify the initial positive
reaction of the screening assay and confirm the results. The blood transfusion
services worldwide require a very sensitive and specific assay for vCJD.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890